Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70) announced on November 18, 2026, that all matters put before shareholders at its annual general meeting were approved. The meeting saw 2,824,597 common shares voted, representing 34.93% of the 8,086,889 shares issued and outstanding as of the record date. Key outcomes included the election of three directors and the approval of the company's equity incentive plan, providing governance continuity for the Kelowna, British Columbia-based oral stimulant pouch company.

Key Points

  • Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70) held its annual general meeting on November 18, 2026
  • All resolutions were approved, including director elections and auditor re-appointment
  • 34.93% of issued and outstanding shares were represented at the meeting
  • Investors may watch for further operational updates following the governance resolutions confirmed at the meeting

Director Elections and Auditor Approval at Doseology's AGM

Shareholders elected Kareem Baalbaki, Jeremy Wright, and Scott Reeves to serve on Doseology's board of directors. The re-appointment of Dale Matheson Carr-Hilton Labonte LLP, Chartered Professional Accountants, as the company's auditor was also approved at the meeting. These outcomes establish the company's core governance structure as it continues operating in the oral stimulant pouch market. The release states that all matters put to a vote were approved without exception, providing a clear mandate for the current leadership team to proceed with the company's strategic direction.

Omnibus Equity Incentive Plan Greenlit by MOOD Shareholders

Shareholders also approved Doseology's omnibus equity incentive compensation plan, in accordance with the requirements of the Canadian Securities Exchange. Such plans typically allow companies to grant equity-based compensation to directors, officers, employees, and consultants, though the specific terms and maximum share limits of Doseology's plan were not disclosed in the announcement. Approval of the plan provides the board with a formal framework for aligning compensation with shareholder interests, a governance measure that investors in small-cap CSE-listed companies often monitor closely.

Doseology's Position in the Oral Stimulant Pouch Sector

Doseology Sciences specialises in pouch-based oral stimulant and cognitive support products, operating in a category the company describes as one of the most dynamic segments of modern functional consumer products. The release highlights growing consumer demand for smokeless, vapour-free alternatives to combustible tobacco and vape products, with oral pouches positioned as a convenient and discreet delivery format. The immediate share price impact of the AGM results was not clear from available public information.